Physical Training in Sarcoidosis Patients
1 other identifier
interventional
40
1 country
1
Brief Summary
Exercise intolerance, muscle weakness and fatigue complaints are frequent and persistent problems in sarcoidosis. These physical impairments are disabling and affect quality of life in a negative way. The aetiology of these physical impairments is multifactorial. Physical inactivity can cause deconditioning, resulting in more perceived fatigue and muscle weakness. These symptoms may be partially reversible following a structured physical training program. However, scientific studies about physical training in sarcoidosis are lacking. Therefore, the aim of the present study is to examine the changes in fatigue complaints, physical functioning and quality of life (QOL) in patients with sarcoidosis following a 13-week physical training program. After obtaining written informed consent, sarcoidosis patients will start a 13-week physical training program for three times a week. This training program includes peripheral muscle training for both the upper and lower extremities (starting at 40% of the multiple-repetition maximum) and endurance training consisting of walking on a treadmill (starting at 60% of the speed of the 6-minute walk test) or cycling on a ergometer (starting at 50% of the Wmax). Participants will be assessed at baseline (week 0), at the end (13 weeks) and 3 months after ending the training. During these assessments, patients perform muscle strength (m. quadriceps and m. biceps) and exercise tests (six-minute walk test and submaximal endurance cycling test). They also complete several questionnaires: Fatigue Assessment Scale (FAS), World Health Organization Quality of Life assessment instrument-BREF (WHOQOL-BREF), Small Fiber Neuropathy Screening List (SFNSL), Medical Research Council (MRC), Visual Analogue Scale (VAS) and Hospital Anxiety and Depression Scale (HADS)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
February 18, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2014
CompletedFirst Posted
Study publicly available on registry
September 18, 2014
CompletedJanuary 9, 2018
September 1, 2014
1.2 years
February 18, 2013
January 5, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cange in Fatigue Assessment Scale (FAS)at 3 months after end of the training
The 10-item FAS is a fatigue scale. Each item has a 5-point rating scale and FAS scores range from 10-50. FAS scores \<22 indicate nonfatigue persons and scores of 22-34 indicate fatigued persons.
baseline (week 0), at the end (week 13) and 3 months after ending the training
Study Arms (1)
Physical training
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Patients are diagnosed with sarcoidosis according to the WASOG guideline.
- Fatigued patients ((FAS-score ≥ 22 points) and/or a reduced six-minute walking distance (predicted six-minute walking distance -50 m).
- Patients who signed the consent form and are able to participate in a training program.
- Minimum age 18 years and maximum age 70 years.
- Clinically stable: no exacerbation of complaints, or changes in initiated therapeutic management during the preceding 3 months.
You may not qualify if:
- Patients with a cognitive failure, making them unable to understand questionnaires and instructions.
- Patients with a oncological, cardiac, neurological or orthopedic history making them unable to participate in a training program.
- Patients who are unfamiliar with the Dutch language, disabling them to understand questionnaires and instructions.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Maastricht University Medical Centerlead
- ild care foundationcollaborator
Study Sites (1)
Fysiomedica
Geleen, Limburg, 6161 ST, Netherlands
Related Publications (3)
Marcellis RG, Lenssen AF, de Vries GJ, Baughman RP, van der Grinten CP, Verschakelen JA, De Vries J, Drent M. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung. 2013 Feb;191(1):43-52. doi: 10.1007/s00408-012-9432-6. Epub 2012 Nov 9.
PMID: 23138855BACKGROUNDMarcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Sep;38(3):628-34. doi: 10.1183/09031936.00117710. Epub 2011 Mar 24.
PMID: 21436356BACKGROUNDMarcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, Lenssen A. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22;32(1):53-62.
PMID: 26237356DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antoine F. Lenssen, PhD
Maastricht University Medical Centre
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 18, 2013
First Posted
September 18, 2014
Study Start
January 1, 2013
Primary Completion
April 1, 2014
Study Completion
May 1, 2014
Last Updated
January 9, 2018
Record last verified: 2014-09